Pharmacopeia Completes Acquisition of Molecular Simulations Inc.

Pharmacopeia, Inc. this week announced that it has completed its acquisition of Molecular Simulations Inc.

Joseph A. Mollica, chairman, president and CEO of Pharmacopeia says, "We are excited to move forward with the multitude of opportunities this acquisition brings to the combined company. Our technology platform is significantly enhanced by adding MSI's expertise in molecular modeling, simulation, and informatics software."

Pharmacopeia has acquired all of the outstanding stock of MSI for approximately 7.1 million newly issued shares of Pharmacopeia common stock. The name of the company will remain Pharmacopeia and the stock will continue to trade on the Nasdaq National Market under the symbol "PCOP".

Pharmacopeia is a leader in drug discovery combining three platform technologies which include informatics, small molecule combinatorial chemistry, and high-throughput screening. Through its wholly owned subsidiary, Molecular Simulations Inc., Pharmacopeia develops and commercializes molecular modeling, simulation, and informatics software and services.

For more information contact: Sue Rodney, Pharmacopeia, 101 College Rd. East, Princeton, NJ 08540. Tel: 609-452-2434